IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Regel, Ivonne ^a   Eichenmüller, Melanie ^a   Joppien, Saskia ^a   Liebl, Johanna ^b   Häberle, Beate ^a   Müller Höcker, Josef ^b   Vollmar, Angelika ^b   von Schweinitz, Dietrich ^a   Kappler, Roland ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epigenetics; Hepatoblastoma; IGF2; Invasion; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; SOMATOMEDIN BINDING PROTEIN 3; IGFBP3 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER RISK; CELL LINE; CHILDHOOD CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; GENE SILENCING; HUMAN; HUMAN CELL; LIVER CANCER; METASTASIS; VASCULAR TUMOR; CELL MOTION; CELL SURVIVAL; GENETIC EPIGENESIS; GENETICS; IN VITRO STUDY; LIVER TUMOR; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; EPIGENESIS, GENETIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; LIVER NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84857952904     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-9     Document Type: Article

References (47)

1. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983, 14:512-537. 10.1016/S0046-8177(83)80005-7, 6303939.
2. Perilongo G, Shafford E, Plaschkes J. SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 2000, 1:94-100. 10.1016/S1470-2045(00)00018-8, 11905674.
3. Fuchs J, Rydzynski J, Von Schweinitz D, Bode U, Hecker H, Weinel P, Burger D, Harms D, Erttmann R, Oldhafer K, Mildenberger H. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002, 95:172-182. 10.1002/cncr.10632, 12115331.
4. Haberle B, Bode U, von Schweinitz D. Differentiated treatment protocols for high- and standard-risk hepatoblastoma-an interim report of the German Liver Tumor Study HB99. Klin Padiatr 2003, 215:159-165.
5. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004, 4:505-518. 10.1038/nrc1387, 15229476.
6. Scotting PJ, Walker DA, Perilongo G. Childhood solid tumours: a developmental disorder. Nat Rev Cancer 2005, 5:481-488. 10.1038/nrc1633, 15905853.
7. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, Pietsch T. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000, 157:1393-1403. 10.1016/S0002-9440(10)64652-4, 1850179, 11021841.
8. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995, 11:221-229.
9. Honda S, Arai Y, Haruta M, Sasaki F, Ohira M, Yamaoka H, Horie H, Nakagawara A, Hiyama E, Todo S, Kaneko Y. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 2008, 99:1891-1899. 10.1038/sj.bjc.6604754, 2600691, 19034281.
10. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M, von Schweinitz D, Koch A, Fonatsch C, Pietsch T, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 2004, 39:126-137. 10.1002/gcc.10307, 14695992.
11. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997, 8:45-62. 10.1016/S1359-6101(96)00053-6, 9174662.
12. Modric T, Silha JV, Shi Z, Gui Y, Suwanichkul A, Durham SK, Powell DR, Murphy LJ. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 2001, 142:1958-1967. 10.1210/en.142.5.1958, 11316761.
13. Hochscheid R, Jaques G, Wegmann B. Transfection of human insulin-like growth factor-binding protein 3 gene inhibits cell growth and tumorigenicity: a cell culture model for lung cancer. J Endocrinol 2000, 166:553-563. 10.1677/joe.0.1660553, 10974650.
14. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997, 272:12181-12188. 10.1074/jbc.272.18.12181, 9115291.
15. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000, 60:22-27.
16. Zou T, Fleisher AS, Kong D, Yin J, Souza RF, Wang S, Smolinski KN, Abraham JM, Meltzer SJ. Sequence alterations of insulin-like growth factor binding protein 3 in neoplastic and normal gastrointestinal tissues. Cancer Res 1998, 58:4802-4804.
17. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, et al. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002, 176:149-158. 10.1016/S0304-3835(01)00736-4, 11804742.
18. Tomii K, Tsukuda K, Toyooka S, Dote H, Hanafusa T, Asano H, Naitou M, Doihara H, Kisimoto T, Katayama H, et al. Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers. Int J Cancer 2007, 120:566-573. 10.1002/ijc.22341, 17096329.
19. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116. 10.1038/nrc1799, 16491070.
20. Subramaniam K, Ooi LL, Hui KM. Transcriptional down-regulation of IGFBP-3 in human hepatocellular carcinoma cells is mediated by the binding of TIA-1 to its AT-rich element in the 3'-untranslated region. Cancer Lett 2010, 297:259-268. 10.1016/j.canlet.2010.05.019, 20599318.
21. Gray SG, Kytola S, Lui WO, Larsson C, Ekstrom TJ. Modulating IGFBP-3 expression by trichostatin A: potential therapeutic role in the treatment of hepatocellular carcinoma. Int J Mol Med 2000, 5:33-41.
22. Luo SM, Tan WM, Deng WX, Zhuang SM, Luo JW. Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 2005, 11:4272-4276.
23. Dar AA, Majid S, Nosrati M, de Semir D, Federman S, Kashani-Sabet M. Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol 2010, 130:2071-2079. 10.1038/jid.2010.70, 3023991, 20357812.
24. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 10.1016/j.cell.2007.06.009, 2756685, 17604717.
25. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928. 10.1038/nrc2536, 19029956.
26. Gray SG, Eriksson T, Ekstrom C, Holm S, von Schweinitz D, Kogner P, Sandstedt B, Pietsch T, Ekstrom TJ. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000, 82:1561-1567. 10.1054/bjoc.1999.1179, 2363389, 10789725.
27. Hartmann W, Kuchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, et al. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009, 15:4538-4545. 10.1158/1078-0432.CCR-08-2878, 19584164.
28. Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 2006, 16:210-218. 10.1111/j.1525-1438.2006.00299.x, 16445635.
29. de Ibanez Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006, 66:5021-5028. 10.1158/0008-5472.CAN-05-3365, 16707423.
30. Antequera F, Boyes J, Bird A. High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 1990, 62:503-514. 10.1016/0092-8674(90)90015-7, 1974172.
31. Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003, 63:1114-1121.
32. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001, 10:1413-1419. 10.1093/hmg/10.13.1413, 11440994.
33. Shen Y, Chow J, Wang Z, Fan G. Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells. Hum Mol Genet 2006, 15:2623-2635. 10.1093/hmg/ddl188, 16870691.
34. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3669-3675.
35. Chang YS, Wang L, Suh YA, Mao L, Karpen SJ, Khuri FR, Hong WK, Lee HY. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 2004, 23:6569-6580. 10.1038/sj.onc.1207882, 15247904.
36. Perry AS, Loftus B, Moroose R, Lynch TH, Hollywood D, Watson RW, Woodson K, Lawler M. In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. Br J Cancer 2007, 96:1587-1594. 10.1038/sj.bjc.6603767, 2359953, 17453001.
37. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007, 117:2713-2722. 10.1172/JCI31457, 1950459, 17717605.
38. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007, 212:330-344. 10.1002/jcp.21066, 17458893.
39. Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y, Hosoi F, Maruyama Y, et al. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 2006, 97:1182-1190. 10.1111/j.1349-7006.2006.00322.x, 16965600.
40. Kappler R, von Schweinitz D. Molecular aspects of hepatoblastoma. Pediatric Liver Tumors 2011, 27-42. Heidelberg: Springer, Zimmermann A, Perilongo G.
41. Pietsch T, Fonatsch C, Albrecht S, Maschek H, Wolf HK, von Schweinitz D. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest 1996, 74:809-818.
42. Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol 2009, 40:1512-1515.
43. Eichenmuller M, Gruner I, Hagl B, Haberle B, Muller-Hocker J, von Schweinitz D, Kappler R. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009, 49:482-490. 10.1002/hep.22649, 19177589.
44. Specht K, Kremer M, Muller U, Dirnhofer S, Rosemann M, Hofler H, Quintanilla-Martinez L, Fend F. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res 2002, 8:2902-2911.
45. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
46. Fridman AL, Rosati R, Li Q, Tainsky MA. Epigenetic and functional analysis of IGFBP3 and IGFBPrP1 in cellular immortalization. Biochem Biophys Res Commun 2007, 357:785-791. 10.1016/j.bbrc.2007.04.019, 17451653.
47. Eichenmuller M, von Schweinitz D, Kappler R. Betulinic acid treatment promotes apoptosis in hepatoblastoma cells. Int J Oncol 2009, 35:873-879.